Beam Therapeutics Inc (NASDAQ: BEAM) is 10.56% higher on its value in year-to-date trading and has touched a low of $20.84 and a high of $37.49 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BEAM stock was last observed hovering at around $26.42 in the last trading session, with the day’s gains setting it 1.0%.
Currently trading at $27.42, the stock is -4.73% and 1.62% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.3 million and changing 3.80% at the moment leaves the stock 6.20% off its SMA200. BEAM registered -26.94% loss for a year compared to 6-month gain of 17.18%.
The stock witnessed a 3.20% loss in the last 1 month and extending the period to 3 months gives it a 2.66%, and is 5.02% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.76% over the week and 9.37% over the month.
Beam Therapeutics Inc (BEAM) has around 483 employees, a market worth around $2.64B and $63.52M in sales. Profit margin for the company is -593.13%. Distance from 52-week low is 31.57% and -26.86% from its 52-week high. The company has generated returns on investments over the last 12 months (-42.74%).
with sales reaching $14.9M over the same period.The EPS is expected to shrink by -5.84% this year, but quarterly earnings will post 1.86% year-over-year. Quarterly sales are estimated to grow 101.12% in year-over-year returns.
The shares outstanding are 83.63M, and float is at 73.79M with Short Float at 13.54%.
The top institutional shareholder in the company is VANGUARD GROUP INC with over 7.9 million shares valued at $185.11 million. The investor’s holdings represent 9.6701 of the BEAM Shares outstanding. As of 2024-06-30, the second largest holder is FARALLON CAPITAL MANAGEMENT LLC with 7.91 million shares valued at $185.4 million to account for 9.6135 of the shares outstanding. The other top investors are BLACKROCK INC. which holds 7.63 million shares representing 9.3446 and valued at over $178.87 million, while ARK INVESTMENT MANAGEMENT LLC holds 9.2649 of the shares totaling 7.63 million with a market value of $178.68 million.
Beam Therapeutics Inc (BEAM) Insider Activity
The most recent transaction is an insider sale by Cavanagh Bethany J, the company’s SVP, Finance and Treasurer. SEC filings show that Cavanagh Bethany J sold 6,287 shares of the company’s common stock on Feb 18 ’25 at a price of $35.00 per share for a total of $0.22 million. Following the sale, the insider now owns 37527.0 shares.
Beam Therapeutics Inc disclosed in a document filed with the SEC on Feb 14 ’25 that Bellon Christine (Chief Legal Officer) sold a total of 10,000 shares of the company’s common stock. The trade occurred on Feb 14 ’25 and was made at $34.00 per share for $0.34 million. Following the transaction, the insider now directly holds 0.1 million shares of the BEAM stock.
Still, SEC filings show that on Feb 14 ’25, CHRISTINE BELLON (Officer) Proposed Sale 10,000 shares at an average price of $34.00 for $0.34 million. The insider now directly holds shares of Beam Therapeutics Inc (BEAM).
